R. Brent Jones' departure as Chief Financial Officer of Avantor, Inc. was reported; the filing names no successor. As of November 6, 2026, Avantor, Inc. has reported 5 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 1, 2026 to September 21, 2026, naming 2 appointments and 1 departure (Form 8-K, April 1, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Avantor, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Todd Garner · 8-K, 2026-09-21
- · In / out: In · Person: Todd Garner · 8-K, 2026-09-21
- · In / out: Reported · Person: not named in the filing · 8-K/A, 2026-08-27
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-23
- · In / out: Out · Person: R. Brent Jones · Role: Chief Financial Officer · 8-K, 2026-04-01
Avantor, Inc. reported changes in 5 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-01 to 2026-09-21. They name 2 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Avantor, Inc. files it.
Also on the record for Avantor, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.29% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 4.8% of the class | 5%+ stakes | Source |
| October 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 8.7% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 8.3% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13G/A, by Dodge & Cox | 17.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Avantor, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Avantor, Inc. and the records around it.
Avantor, Inc. elsewhere on the record
Companies that share a holder
- Dodge & Cox also filed stake reports on 36 other companies: Charter Communications, Inc. (Aug 2026), SUN COMMUNITIES, INC (Aug 2026), TransUnion (Jun 2026)
- T. Rowe Price Investment Management, Inc. also filed stake reports on 167 other companies: CABALETTA BIO INC (Nov 2026), MADISON SQUARE GARDEN SPORTS CORP (Nov 2026), MSG RANGERS CORP (Nov 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Watch Avantor, Inc.
Get an email when Avantor, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Avantor, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Avantor, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Avantor, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-21 | In | 8-K, 2026-09-21 | |||
| 2026-09-21 | In | 8-K, 2026-09-21 | |||
| 2026-08-27 | Reported | not named in the filing | 8-K/A, 2026-08-27 | ||
| 2026-04-23 | Reported | not named in the filing | 8-K, 2026-04-23 | ||
| 2026-04-01 | Out | Chief Financial Officer | 8-K, 2026-04-01 |
Who leads Avantor, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: R. Brent Jones, departure reported (filed 2026-04-01). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Avantor, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Avantor, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Avantor, Inc.Every change, in the filing's words
Appointed: Todd Garner
Upon the Commencement Date, Mr. Garner will become a member of the Company's Executive Leadership Team and serve as its principal financial officer.
- On September 21, 2026, Avantor, Inc. (the "Company"), announced the appointment of Todd Garner as Executive Vice President and Chief Financial Officer, effective as of September 21, 2026 (the "Commencement Date").
- Prior to joining the Company, Mr. Garner, age 57, served as Executive Vice President and Chief Financial Officer of CONMED Corporation, a medical technology company, from January 2018 until March 2026.
- Prior to that, Mr. Garner served in several roles at C.R. Bard, Inc, a specialty medical products company, from 2003 until 2017, including Vice President, Investor Relations from 2011 until 2017, Vice President, Controller (Division Chief Financial Officer) from 2007 until 2011, Director of Financial Reporting from 2005 to 2007, and Controller of the Reynosa Operations from 2003 to 2005.
- Mr. Garner holds a bachelor's degree in accounting from Brigham Young University and an MBA from the University of Texas - Rio Grande Valley.
- Mr. Garner is also a Certified Public Accountant.
- In connection with the appointment of Mr. Garner as Executive Vice President and Chief Financial Officer, on September 17, 2026, the Company entered into an employment letter agreement (the "Employment Letter") with Mr. Garner.
Appointed: Todd Garner
Upon the Commencement Date, Mr. Garner will become a member of the Company's Executive Leadership Team and serve as its principal financial officer.
- On September 21, 2026, Avantor, Inc. (the "Company"), announced the appointment of Todd Garner as Executive Vice President and Chief Financial Officer, effective as of September 21, 2026 (the "Commencement Date").
- Prior to joining the Company, Mr. Garner, age 57, served as Executive Vice President and Chief Financial Officer of CONMED Corporation, a medical technology company, from January 2018 until March 2026.
- Prior to that, Mr. Garner served in several roles at C.R. Bard, Inc, a specialty medical products company, from 2003 until 2017, including Vice President, Investor Relations from 2011 until 2017, Vice President, Controller (Division Chief Financial Officer) from 2007 until 2011, Director of Financial Reporting from 2005 to 2007, and Controller of the Reynosa Operations from 2003 to 2005.
- Mr. Garner holds a bachelor's degree in accounting from Brigham Young University and an MBA from the University of Texas - Rio Grande Valley.
- Mr. Garner is also a Certified Public Accountant.
- In connection with the appointment of Mr. Garner as Executive Vice President and Chief Financial Officer, on September 17, 2026, the Company entered into an employment letter agreement (the "Employment Letter") with Mr. Garner.
Reported
On April 23, 2026, Avantor, Inc. (the "Company") filed a Current Report on Form 8-K (the "Original 8-K") disclosing that Benoit Gourdier, the Company's Executive Vice President, Bioscience and Medtech Products, would transition to a new role supporting the Company's segment integration activities for a period of time, after which he would depart the Company.
- The Original 8-K did not include Mr. Gourdier's departure date because, at the time, his departure date had not been determined.
- On August 21, 2026, the Company, through its subsidiary VWR International, LLC, and Mr. Gourdier agreed to a transition arrangement (the "Transition Agreement"), pursuant to which Mr. Gourdier will continue his employment with the Company through October 14, 2026, after which his employment will end.
- If Mr. Gourdier remains employed and complies with the terms of the Transition Agreement until October 14, 2026, he will be entitled to receive severance benefits materially consistent with the terms of the Company's Executive Severance and Change in Control Plan, which are described in the Company's proxy statement filed with the Securities and Exchange Commission on March 27, 2026.
Reported
On April 17, 2026, Avantor, Inc. (the "Company") informed Benoit Gourdier, the Company's Executive Vice President, Bioscience and Medtech Products, that he would be transitioning to a new role supporting the Company's segment integration activities, after which it is expected that he would depart the Company no later than December 31, 2026.
Departing: R. Brent Jones, Chief Financial Officer
On March 26, 2026, Mr. R. Brent Jones notified Avantor, Inc. (the "Company") of his decision to resign as the Company's Executive Vice President and Chief Financial Officer ("CFO") to join a company outside the life sciences industry.
- While a final departure date has not been set, Mr. Jones' employment agreement requires him to provide 90 days' notice before the effectiveness of his resignation, unless waived by the Company.
- Following Mr. Jones' departure, the Company anticipates appointing Steven Eck, the Company's Senior Vice President and Chief Accounting Officer as interim CFO of the Company.
- Mr. Eck will continue to serve in his current role and retain his responsibilities as the Company's principal accounting officer while the Company undertakes an executive search process for a permanent CFO.
- Mr. Eck, 50, joined the Company in 2019 as Senior Vice President and Chief Accounting Officer.
- Before joining the Company, Mr. Eck previously served as the principal accounting officer of CSS Industries, Inc., a consumer products company, from June 2018 to April 2019.
- Prior to joining CSS Industries in 2018, Mr. Eck served as a Vice President of Finance and in other senior level finance positions at Fidelity National Information Systems, a financial technology and payments company, between 2014 and 2018.
- Mr. Eck also served in senior accounting roles at Gardner Denver, Inc., an industrial manufacturer, and at General Electric Company, a high-tech industrial company, between 2010 and 2014.
- Mr. Eck began his professional career in 2001 at Deloitte & Touche LLP.
Tools for this story
Each opens in a new tab, filled in for Avantor, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.